Avid Bioservices, Inc. (CDMO)
Market Cap | 1.01B |
Revenue (ttm) | 134.18M |
Net Income (ttm) | 118.25M |
Shares Out | 62.31M |
EPS (ttm) | 1.69 |
PE Ratio | 9.58 |
Forward PE | 81.30 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 451,486 |
Open | 16.31 |
Previous Close | 16.62 |
Day's Range | 16.09 - 17.09 |
52-Week Range | 11.30 - 22.83 |
Beta | 1.85 |
Analysts | Buy |
Price Target | 22.78 (+40.7%) |
Earnings Date | Mar 6, 2023 |
About CDMO
Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services focused on biopharmaceutical drug substances derived from mammalian cell culture. The company produces monoclonal antibodies and recombinant proteins; and offers services, including CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, and regulatory submission and support. It also provides var... [Read more]
Financial Performance
In 2022, CDMO's revenue was $119.60 million, an increase of 24.75% compared to the previous year's $95.87 million. Earnings were $127.67 million, an increase of 3747.86%.
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for CDMO stock is "Buy." The 12-month stock price forecast is $22.78, which is an increase of 40.70% from the latest price.
News

Avid Bioservices (CDMO) Reports Q2 Loss, Tops Revenue Estimates
Avid Bioservices (CDMO) delivered earnings and revenue surprises of 0% and 12.12%, respectively, for the quarter ended October 2022. Do the numbers hold clues to what lies ahead for the stock?

Avid Bioservices Reports Financial Results for Second Quarter Ended October 31, 2022 and Recent Developments
-- Recorded Second Quarter Revenue of $34.8 Million -- -- Signed $26 Million in Net New Business Orders Resulting in a Backlog of $147 Million, an Increase of 23% Year-Over-Year --

Avid Bioservices to Report Financial Results for Second Quarter of Fiscal Year 2023 After Market Close on December 6, 2022
TUSTIN, Calif., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient live...

Avid Bioservices Appoints Oksana Lukash as Vice President, People
TUSTIN, Calif., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient live...

Avid Bioservices to Participate in the Credit Suisse 31st Annual Healthcare Conference
TUSTIN, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient live...

Does Avid Bioservices (CDMO) Have the Potential to Rally 61% as Wall Street Analysts Expect?
The consensus price target hints at a 60.5% upside potential for Avid Bioservices (CDMO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings ...

Avid Bioservices to Participate in RBC Global CDMO Conference
TUSTIN, Calif., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient liv...

Avid Bioservices Appoints Michael Alston, Jr. as Vice President, Operations
Accomplished Operations Professional Promoted from Role as Director of Project Engineering; Credited with Leading All of the Company's Ongoing Facility Expansion Projects Accomplished Operations Profe...

Avid Bioservices to Participate in Morgan Stanley 20th Annual Global Healthcare Conference
TUSTIN, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient liv...

Avid Bioservices (CDMO) Beats Q1 Earnings and Revenue Estimates
Avid Bioservices (CDMO) delivered earnings and revenue surprises of 33.33% and 7.92%, respectively, for the quarter ended July 2022. Do the numbers hold clues to what lies ahead for the stock?

Avid Bioservices Reports Financial Results for First Quarter Ended July 31, 2022 and Recent Developments
-- Recorded First Quarter Revenue of $36.7 Million -- -- Signed $41 Million in Net New Business Orders and Ended the Quarter with a Record High Backlog of $157 Million --

Avid Bioservices Appoints Pramthesh (Prem) Patel, Ph.D., as Vice President, Process Development for Mammalian Cell Business
Biopharmaceutical Executive with More than 30 Years of Experience With Top Global Big Pharma Companies GSK and Bristol Myers Squibb Biopharmaceutical Executive with More than 30 Years of Experience Wi...

Avid Bioservices to Report Financial Results for First Quarter of Fiscal Year 2023 After Market Close on September 6, 2022
TUSTIN, Calif., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient live...

Avid Bioservices Reports Financial Results for Fourth Quarter and Full Fiscal Year Ended April 30, 2022 and Recent Developments
-- Recorded Fourth Quarter and Full Fiscal Year Revenue of $31 Million and $120 Million, Respectively -- -- Signed $44 Million in Net New Business Orders and Ended the Quarter with a Record High Backl...

Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2022 After Market Close on June 29, 2022
TUSTIN, Calif., June 22, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient live...

Avid Bioservices, Inc. and CRB highlight efforts that enabled opening of first phase of new viral vector facility in California in only eight months
53,000-square-foot facility addresses unique demands of commercial-scale viral vector production COSTA MESA, Calif. , June 16, 2022 /PRNewswire/ -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated co...

Avid Bioservices Announces Launch of Analytical and Process Development Suites Within New, World-Class Viral Vector Development and Manufacturing Facility
AD/PD Laboratories Open Exactly Eight Months After Announced Plans to Build Viral Vector Facility

Avid Bioservices Announces Further Expansion of Process Development Capacity for Mammalian Cell Business
New Laboratories Have Potential to Support an Additional $20 Million in Annual Process Development Revenue, Doubling Current Mammalian Cell Process Development Capacity

Avid Bioservices to Participate in KeyBanc Capital Markets Life Sciences & MedTech Forum
TUSTIN, Calif., March 16, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient liv...

Avid Bioservices (CDMO) Q3 Earnings and Revenues Top Estimates
Avid Bioservices (CDMO) delivered earnings and revenue surprises of 80% and 12.53%, respectively, for the quarter ended January 2022. Do the numbers hold clues to what lies ahead for the stock?

Avid Bioservices to Report Financial Results for Third Quarter of Fiscal Year 2022 after Market Close on March 8, 2022
TUSTIN, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient liv...

Avid Bioservices (CDMO) Stock Sinks As Market Gains: What You Should Know
Avid Bioservices (CDMO) closed the most recent trading day at $21.25, moving -1.16% from the previous trading session.

Avid Bioservices (CDMO) Gains But Lags Market: What You Should Know
Avid Bioservices (CDMO) closed at $18.97 in the latest trading session, marking a +0.53% move from the prior day.

Avid Bioservices Announces Official Opening of Second Downstream Processing Suite Within Myford North Facility
Milestone Marks Completion of First Phase of Two-Part Myford Facility Expansion; First Customer Project to Begin in New Downstream Processing Suite in Coming Month Milestone Marks Completion of First ...

Follow The Leader: 3 Biopharma Stocks Displaying Relative Strength
3 Biopharma Stocks Displaying Relative Strength Heading Into 2022